CA
NZ
UK
AU
IND
US
● AVXL shares surged 14.47% after a fiscal third-quarter update reframed the regulatory path for lead candidate blarcamesine and reassured investors about the company's financial staying power.
● EIKN shares rose 12.46% as investors positioned ahead of the ESMO Congress in late October, where seven abstracts covering the company's pipeline have been accepted.
Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biotech, has expanded its pipeline through a licensing agreement with PharmAla Biotech, adding a new MDMA-based therapeutic candidate alongside its existing Parkinson's disease program.
Liminatus Pharma, Inc. (NASDAQ:LIMN), a clinical-stage biotech, is working through a pivotal stretch involving a proposed merger with oncology cell-therapy company InnocsAI and steps to maintain its Nasdaq listing.
Cytek Biosciences, Inc. (NASDAQ:CTKB) is weighing its next legal steps after a Delaware jury ruled that several of its spectral flow cytometry products infringe a patent held by Beckman Coulter, a Danaher subsidiary, and ordered the company to pay $56 million in damages.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), the synthetic-biology company, continues building out its automated laboratory infrastructure as it works to transition from legacy program revenue toward a platform-based business model.
electroCore, Inc. (NASDAQ:ECOR), the bioelectronic medicine company behind the gammaCore vagus nerve stimulator and the consumer-facing Truvaga device, raised its full-year revenue guidance following strong second-quarter results.
Apnimed, Inc. (NASDAQ:APMD), the Cambridge, Massachusetts drug developer, is advancing its lead sleep-apnea candidate through the FDA review process following a recentNasdaqdebut that raised roughly $220.8 million.
Tempus AI, Inc. (NASDAQ:TEM), the precision-medicine and AI diagnostics company, reported its first GAAP-profitable quarter alongside continued double-digit revenue growth, while advancing a pendingAcquisitionthat would expand its oncology monitoring capabilities.
Serina Therapeutics, Inc. (NYSE American:SER), a clinical-stage biotech, has completed a key enrollment milestone in its Phase 1b trial evaluating SER-252 for advanced Parkinson's disease.
Please wait processing your request...